Clinical trial
Dosing Study of Replagal in Patients With Fabry Disease
NCT00068107 · Baylor Research Institute, Other · Completed
Key facts
| NCT number | NCT00068107 |
|---|---|
| Title | Dosing Study of Replagal in Patients With Fabry Disease |
| Official title | Study of Weekly Dosing Regimens of Replagal in Patients With Fabry Disease With Incomplete Clinical Response to Long-Term Therapy |
| Lead sponsor | Baylor Research Institute, Other |
| Collaborators | National Institute of Neurological Disorders and Stroke (NINDS) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | Replagal |
| Enrollment | 13 |
| Start date | Sep 1, 2003 |
| Primary completion | Dec 1, 2013 |
| Completion | Dec 1, 2013 |
| First posted | Sep 8, 2003 |
| Last update posted | Mar 31, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: